IL-23p40 vaccine

The IL-23p40 vaccine is an experimental **peptide-based vaccine** designed to induce autoantibodies against the p40 subunit shared by IL-12 and IL-23, two key pro-inflammatory cytokines. The vaccine employs a **virus-like particle (VLP) platform** to present p40 peptide antigens and stimulate an immune response that generates long-lasting IgG antibodies against IL-12, IL-23, and the p40 subunit[2][3]. By blocking IL-12 and IL-23 signaling, the vaccine aims to suppress both Th1 and Th17 inflammatory pathways, which are implicated in various immune-mediated inflammatory diseases. The vaccine has demonstrated efficacy in preclinical models of inflammatory bowel disease (IBD), atopic dermatitis, and asthma, showing reduced intestinal inflammation, fibrosis, and airway inflammation[2][3][4]. The mechanism involves rebalancing Th1/Th17/Treg responses and increasing IL-10 production from dendritic cells[2]. This active immunization strategy offers a potential long-term therapeutic approach compared to short-acting monoclonal antibodies.

Other names

IL-12/IL-23p40 vaccinep40 vaccinep-40 vaccinep 40 vaccinep40 peptide vaccinep-40 peptide vaccinep 40 peptide vaccineIL-12/IL-23p40 peptide-based vaccineIL-23p40 peptide-based vaccineIL23p40 peptide-based vaccineIL 23p40 peptide-based vaccine